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Introduction  and  objectives:  We  aimed  to  build  a  national  consensus  to  optimize  the  use  of  oral
corticosteroids  (OCS)  in  severe  asthma  in  Portugal.
Material  and  methods:  A  modified  3-round  Delphi  including  65  statements  (topics  on  chronic
systemic corticotherapy,  therapeutic  schemes,  asthma  safety  and  monitoring)  was  performed
via online  platform  (October-November  2019).  A  five-point  Likert-type  scale  was  used  (1-
‘strongly disagree’;  5-‘strongly  agree’).  Consensus  threshold  was  established  as  a  percentage
of agreement  among  participants  ≥90%  in  the  1st  round  and  ≥85%  in  the  2nd  and  3rd  rounds.
The level  of  consensus  achieved  by  the  panel  was  discussed  with  the  participants  (face-to-face
meeting).
Results: Forty-eight  expert  physicians  in  severe  asthma  (specialists  in  allergology  and  pul-
the  study.  Almost  half  of  the  statements  (28/65;  43.1%)  obtained
nd  of  round  one.  By  the  end  of  the  exercise,  12  (18.5%)  statementsmonology)  participated  in  
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did  not  achieve  consensus.  Overall,  87%  of  physicians  agree  that  further  actions  for  OCS  cumu-
lative risk  assessment  in  acute  asthma  exacerbations  are  needed.  The  vast  majority  (91.7%)
demonstrated  a  favorable  perception  for  using  biological  agents  whenever  patients  are  eligible.
Most participants  (95.8%)  are  more  willing  to  accept  some  degree  of  lung  function  deterioration
compared  to  other  outcomes  (worsening  of  symptoms,  quality  of  life)  when  reducing  OCS  dose.
Monitoring  patients’  comorbidities  was  rated  as  imperative  by  all  experts.
Conclusions:  :  These  results  can  guide  an  update  on  asthma  management  in  Portugal  and  should
be supplemented  by  studies  on  therapy  access,  patients’  adherence,  and  costs.
© 2020  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
















































































sthma  is  a  chronic  inflammatory  disease  of  the  airways  that
eads  to  wheezing,  dyspnea,  cough,  and  breathing  difficul-
ies  as  a  consequence  of  generalized  airway  obstruction.  In
ortugal,  the  overall  prevalence  of  asthma  is  around  10.5%
95%  CI  9.5--11.6)  of  the  population.1 There  are  different
orms  (phenotypes)  of  this  condition,  with  different  clin-
cal  features,  including  comorbidities,  severity,  treatment
esponse  and  rates  of  acute  exacerbations.2
Asthma  control  represents  a  main  goal  for  the  mana-
ement  of  the  disease  and  the  impairment  of  patient’s
uality  of  life  is  now  considered  a  serious  outcome  in
linical  trials  and  thus  should  be  routinely  evaluated  by
alidated  questionnaires.3 Patients  with  mild  to  moder-
te  asthma  are  usually  treated  with  inhaled  corticosteroids
ICS),  sometimes  at  higher  doses  and  associated  with  long-
cting  beta-agonists  (LABA)  or  other  therapies.  If  necessary,
n  a  flare-up  where  treated  adults  do  not  respond  to  a  four-
ime  increase  in  baseline  dose  of  ICS,  oral  corticosteroids
OCS)  may  be  used  for  short-term  periods.,  this  corresponds
o  40−50  mg  of  prednisone  or  equivalent  for  5--7  days.4--6
Severe  asthma  occurs  in  5-10%  of  patients  and  is  often
haracterized  by  an  insufficient  response  to  ICS  (i.e.  refrac-
ory  to  conventional  therapy),  especially  in  some  subsets
f  patients  (e.g.  obese),  where  the  severity  might  amelio-
ate  with  specific  strategies.7--10 These  patients  contribute
o  50-60%  of  asthma  costs  and  are  responsible  for  most
f  the  hospitalizations,  admissions  to  emergency  services
nd  deaths  from  asthma.4--6 In  Portugal,  the  annual  cost  of
atients  with  asthma  has  a  significant  impact  on  the  National
ealth  System  which  is  mainly  associated  with  emergency
ervices  (30.7%)  and  treatments  (37.4%).  For  uncontrolled
sthmatics,  the  annual  cost  exceeds  twice  the  costs  of  con-
rolled  patients.11
Currently,  in  severe  patients  without  disease  control
ue  to  frequent  asthma  symptoms  or  frequent  exacerba-
ions  despite  optimal  treatment,  the  additional  use  of  OCS,
r  even  biologic  agents  (monoclonal  antibodies)  represent
herapeutic  alternatives.  As  reported  in  the  SANI  registry
nd  also  in  a  French  study,  over  60%  of  patients  with  severe
12--14Please  cite  this  article  in  press  as:  Chav
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sthma  are  on  regular  oral  corticosteroid  treatment.
ow-dose  OCS  (≤  7.5  mg/day  of  prednisone  equivalent)  com-
ined  with  other  therapies  can  be  effective  for  some  adults





iated  with  considerable  adverse  effects  (evidence  level
),  which  may  influence  patient’s  quality  of  life  and  aug-
ent  treatment  costs.4,5,15 A  systematic  review  published  by
ochrane  Collaboration  (18  clinical  trials;  n  =  2438  patients),
oncluded  that  the  evidence  on  the  best  treatment  scheme
s  still  weak  (whether  lower  dose  or  short-term  regimens
f  OCS  in  asthma  are  less  effective/safe  than  those  with
igher  doses  or  prolonged  regimens).16 Patients  with  severe
sthma  and  T2-type  inflammation  respond  to  OCS  and  often
equire  high  and  continuous  dosages,  contrary  to  T2-low
sthma  patients  who  have  poor  responsiveness  to  corticos-
eroid  treatment.  It  was  not  until  recently,  in  the  era  of
idespread  corticosteroid  treatment  for  all  patients  with
sthma,  that  it  became  evident  that  not  all  patients  respond
qually  well  to  this  treatment  approach.17,18 In  this  context,
t  can  be  assumed  that  the  chronic  use  of  OCS  in  asthma
as  been  gradually  replaced  by  therapies  that  target  spe-
ific  inflammatory  pathways  involved  in  the  pathogenesis  of
sthma  that  are  already  available  such  as  the  biologic  agents
or  patients  with  T2-type  inflammation.19,20
Thus,  given  the  severity  of  asthma  along  with  an  unclear
reatment  algorithm  for  patients  with  different  phenotypes,
he  overuse  of  corticosteroids  in  practice  and  the  diversity  of
ealthcare  settings  dealing  with  asthma  patients,  we  aimed
o  build  a  national  consensus  towards  the  optimization  of
he  use  of  OCS  in  adults  with  severe  asthma.
aterial and methods
tudy  design
his  study  was  designed  as  a  modified  3-round  Delphi
xercise21,22 to  obtain  possible  agreement  on  the  topic  of
ptimizing  the  use  of  oral  corticosteroids  in  adults  with
evere  asthma,  among  a broad  panel  of  medical  experts  in
sthma.
The  scientific  committee  comprised  six  experts  with
xperience  in  the  treatment  of  severe  asthma,  with
ifferent  backgrounds,  namely  pulmonology  and  immunoal-
ergology,  and  one  epidemiologist.  The  expert  panel
elected  by  the  scientific  committee  consisted  of  48  physi-es  Loureiro  C,  et  al.  Pulmonol.  2020.
ians  (specialists  in  allergology  and  pulmonology),  from
ublic  and  private  institutions  (with  clinical  and  academic
xpertise  in  the  management  of  asthma),  and  with  a  wide
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Reducing  oral  corticosteroids  in  severe  asthma  (ROSA  Projec
aspects  (North,  Center  and  South  Portugal).  Because  the  sur-
vey  was  completed  anonymously  and  no  personal  data  were
collected,  institutional  review  board  approval  was  not  nec-
essary.  The  research  assistance  team,  which  directed  and
oversaw  the  entire  process,  was  responsible  for  the  distri-
bution  and  analysis  of  the  questionnaires.
Delphi  rounds  and  consensus  meeting
The  Delphi  questionnaire  was  developed  by  the  scientific
committee  and  initially  included  65  statements  (items),  for-
mulated  in  Portuguese,  grouped  into  three  main  topics:
(1)  Chronic  Systemic  Corticotherapy  (CSC)  in  Asthma  (n  =  19
items);  (2)  Therapeutic  Schemes  of  Systemic  Corticotherapy
in  Crisis  and  Maintenance  (n  =  26  items);  (3)  Asthma  Safety
and  Monitoring  (n  =  20  items).
The  panel  of  experts  should  answer  each  statement
with  their  degree  of  agreement,  using  a  five-point,  ordi-
nal,  Likert-type  scale.  The  scale  was  rated  as  1-  ‘strongly
disagree’,  2-  ‘disagree’,  3-  ‘neither  agree  nor  disagree’,  4-
‘agree’  and  5-  ‘strongly  agree’.  Additionally,  panel  members
during  rounds  1  and  2  had  the  opportunity  to  add  comments
to  each  statement  in  free-text  boxes.  The  modified  Delphi
study  ran  between  October  2019  and  November  2019.  Pan-
elists  answered  via  an  online  survey  platform  for  each  round
(Welphi  Platform).
The  research  assistance  team  assessed  and  presented  the
overall  results  from  each  round  to  all  participants  (groups’
responses  and  individual  response)  to  facilitate  comments
and  clarifications  on  the  statements.
In  2nd  and  3rd  rounds,  panel  members  contrasted  their
previous  round  personal  opinion  with  other  participants’
opinions.  When  they  decided,  participants  were  allowed
to  reassess  their  initial  opinion  on  those  statements  where
consensus  was  not  reached.  In  the  2nd  round,  relevant  com-
ments  from  1st  round  could  originate  statement  rephrasing,
or  addition  of  new  statements,  which  were  individually  eval-
uated  by  the  scientific  committee  before  inclusion  in  Delphi.
After  the  3rd  round,  the  scientific  committee  met  face-
to-face  and,  subsequently  had  a  face-to-face  meeting  with
the  panelists  to  discuss  the  final  results  and  gather  more
in-depth  opinions.
Data  analysis
For  the  purpose  of  the  analysis,  the  answers  given  to  cat-
egories  ‘strongly  agree’  and  ‘agree’,  or  on  the  categories
‘strongly  disagree’  and  ‘disagree’  were  aggregated  into
‘positive  consensus’  and  ‘negative  consensus’,  respectively.
As  convergence  indicators,  the  percentage  variation  of  the
concordance  ratio  between  rounds  was  used.
Consensus  threshold  (cut-off  concordance)  was  estab-
lished  as  a  percentage  of  agreement  among  the  participants
for  each  individual  item  equal  or  greater  to  90%  (≥90%)  in
the  1st  round;  and  equal  or  greater  to  85%  (≥85%)  in  the  2nd
and  3rd  rounds.  A  statement  that  did  not  reach  consensus  on
the  1st  round  was  reconsidered  in  the  following  round  andPlease  cite  this  article  in  press  as:  Chav
https://doi.org/10.1016/j.pulmoe.2020.10.002
so  on.  After  three  rounds,  the  remaining  statements  were
considered  to  have  not  reached  consensus.  The  scores  and
the  level  of  consensus  achieved  by  panelists  were  used  to








verall,  46  of  all  48  invited  panelists  completed  the  three
ounds  of  the  Delphi  consensus  (95.8%  compliance).  No  new
tems  were  proposed  during  the  exercise.  Three  items  (two
rom  topic  1  and  one  from  topic  3)  had  their  text  refor-
ulated  after  the  1st  round  by  the  scientific  committee  to
mprove  interpretability,  as  suggested  by  the  panelists.
Fig.  1  shows  the  flowchart  of  the  Delphi  exercise.  In  the
st  round,  consensus  was  reached  on  28  of  the  65  items
43.1%),  all  of  them  due  agreement  (see  Table  1).  Ten  state-
ents  had  a  concordance  equal  to  100%  (statements  1,  2,  3,
,  11,  20,  44,  54,  61,  62).  Thirty-seven  remaining  items  were
terated  in  the  2nd  round,  where  15  items  (40.5%)  reached
onsensus  (14  in  agreement  and  one  in  disagreement)  (see
able  2).  During  the  3rd  round,  for  the  22  remaining  state-
ents,  10  (45.5%)  obtained  consensus  (nine  in  agreement
nd  one  in  disagreement)  (see  Table  3).  By  the  end  of
he  Delphi  exercise,  twelve  statements  had  not  achieved
onsensus  (18.5%)  (items  5,  17,  22,  23,  31,  33,  39,  42,  46,  52,
3,  64)  (see  Table  4).  See  supplemental  material  (Tables  S1)
or  complete  analysis  in  the  original  language  (Portuguese).
opic  1:  chronic  systemic  corticotherapy  in  asthma
his  topic  aggregated  19  statements.  During  1st  round,  n  =  10
tatements  (52.6%)  obtained  positive  consensus  (categories
strongly  agree’  or  ‘agree’)  (see  Table  1).  The  remaining  nine
tems  did  not  reach  agreement  and,  thus,  were  launched
gain  in  the  2nd  round,  where  n  =  3  (33.3%)  obtained  positive
onsensus  (Table  2).  In  the  last  round,  n  =  4  out  of  the  six
emaining  items  (66.7%)  reached  consensus;  two  items  did
ot  reach  consensus  (10.5%)  (Tables  3  and  4).
opic  2:  therapeutic  schemes  of  systemic
orticotherapy  in  crisis  and  maintenance
his  topic  gathered  26  items,  of  which  n  =  8  (30.7%)  obtained
ositive  consensus  in  the  1st  round  (Table  1).  The  remaining
tatements  were  re-evaluated  in  the  2nd  round,  where  n  =  6
33.3%)  were  positively  consensualized  (Table  2).  The  evalu-
tion  of  the  twelve  items  in  3rd  round,  resulted  in  consensus
or  n  =  6  of  them  (50.0%),  of  which  one  obtained  negative
greement  (Table  3).  Six  other  statements  did  not  reach
onsensus  in  this  topic  (Table  4).
opic  3:  asthma  safety  and  monitoring
his  last  topic  comprised  20  statements.  During  1st  round,
alf  of  the  items  (n  =  10)  obtained  positive  consensus
Table  1),  while  the  others  followed  to  the  next  round.  In
he  2nd  round,  n  =  6  were  consensualized  (60.0%)  (Table  2),
ne  of  them  with  negative  agreement.  In  the  final  round,
one  of  the  remaining  four  items  (20.0%)  reached  consensus
Tables  3  and  4).
Some  variations  in  the  responses  between  rounds  werees  Loureiro  C,  et  al.  Pulmonol.  2020.
bserved.  The  median  variation  in  agreement  rates  between
st  and  2nd  rounds  was  7.4%  [IQR  3.7,  10.1],  while  between
econd  and  third  rounds  was  5.3%  [IQR  2.2,  8.1].  Median






























































Table  1  Results  of  the  Delphi  exercise:  items  reaching  consensus  in  the  1st  round.










1  1  An  objective  evaluation  and  optimization  of  therapeutic
noncompliance  in  patients  with  severe  uncontrolled  asthma  are
crucial  for  the  correct  diagnosis  of  severe  asthma.
100.0%  0.0%  0.0%  48  1  st
1 2  Differential  diagnosis  and  the  identification  and  treatment
optimization  of  comorbidities  that  interfere  with  asthma  control
are of  major  relevance  for  the  correct  diagnosis  of  severe  asthma.
100.0%  0.0%  0.0%  48  1  st
1 3  Inhaled  therapy  should  be  maximized  in  severe  asthma.  100.0%  0.0%  0.0%  48  1  st
1 4  Treatment  of  severe  asthma  should  be  driven  by  clinical  criteria
alongside  with  the  evaluation  of  the  mechanisms  involved  in  the
disease  (with  the  aid  of  markers  e.g.  peripheral  blood  eosinophil
count,  total  serum  IgE,  skin  tests,  nitric  oxide  (FeNO)  and  induced
sputum  cell  count)
97.9%  0.0%  2.1%  48  1  st
1 7  Systemic  corticosteroids  may  be  used  in  moderate  to  severe
asthma  exacerbations,  but  NOT  as  front  line  to  manage  severe
asthma  in  the  long  term.
95.8%  4.2%  0.0%  48  1  st
1 9  Chronic  exposure  to  systemic  corticosteroids  is  significantly
associated  with  an  increase  of  adverse  events,  such  as  infections,
cardiovascular,  metabolic,  psychiatric,  ocular,  gastrointestinal
and bone  complications.
100.0%  0.0%  0.0%  48  1  st
1 11  Biologic  agents  allowing  a  reduction  in  systemic  corticosteroids
usage  should  be  preferred  as  adjuvant  therapy  in  eligible  patients
with  severe  asthma.
100.0%  0.0%  0.0%  48  1  st
1 12  Whenever  eligible,  asthmatic  patients  already  dependent  of
systemic  corticotherapy  should  be  offered  biologic  agent  therapy.
97.9%  2.1%  0.0%  48  1  st
1 16  A  severe  asthma  patient  with  more  than  2  severe  asthma
exacerbations  treated  with  systemic  corticosteroids,  or  an
asthma  related  hospitalization  in  the  last/past  year,  whenever
eligible,  should  be  treated  with  a  biologic  agent.
91.7%  8.3%  0.0%  48  1  st
2 19  Patients  with  uncontrolled  severe  asthma  which  are  not  eligible
for biologics  and  treated  with  OCS,  should  have  its  effectiveness
evaluated  in  3-6  months.  That  evaluation  should  be  based  in  the
change of  the  outcomes  previously  defined  for  that  specific
patient.



































































Table  1  (Continued)










2  20  The  lowest  effective  dose  of  systemic  corticosteroids  should  be
used in  the  control  of  asthma.
100.0%  0.0%  0.0%  48  1  st
2 21  An  understanding  about  the  best  disease  control  should  be
pre-established  with  the  patient,  concerning  various  parameters
to be  considered,  as  exacerbations,  symptoms,  quality  of  life,
respiratory  function  or  adverse  effects  of  therapy.
95.8%  2.1%  2.1%  48  1  st
2 26  In  uncontrolled  severe  asthmatic  patients,  maximum  daily  doses
of systemic  corticosteroids  should  be  the  minimum  needed  dose
to reach  symptom  relief  and  to  reduce  annual  exacerbations
93.8%  2.0%  4.2%  48  1  st
2 36  Sudden  interruption  of  chronic  systemic  corticosteroid  therapy  is
not recommended.
93.8%  4.2%  2.0%  48  1  st
2 38  In  stable  patients  receiving  high  doses  of  ICS  /  LABA  and  oral
corticosteroids,  a  reduction  in  the  dose  of  chronic  systemic
corticosteroids  is  recommended.
95.8%  2.1%  2.1%  48  1  st
2 41  The  use  of  depot  injectable  corticosteroids  should  be  avoided. 97.9%  2.1%  0.0%  48  1  st
2 43  The  decision  to  treat  asthma  with  chronic  systemic  corticosteroids
should  be  assessed  on  the  therapy  benefit/risk  balance.
95.8%  0.0%  4.2%  48  1  st
2 44  Continuous  development  of  alternative  therapies  for  the
management  of  asthma  exacerbations  and  severe  asthma  are
necessary  to  reduce  exposure  to  systemic  corticosteroids.
100.0%  0.0%  0.0%  48  1  st
3 47  Sudden  reduction  in  the  dose  of  chronic  systemic  corticosteroids
may be  associated  with  symptoms  of  adrenal  suppression,  a  side
effect that  must  be  avoided.






























































Table  1  (Continued)










3  50  Adverse  events  related  to  the  use  of  chronic  systemic
corticosteroid  therapy  are  dose  dependent  and  cumulative  over
time.
97.9%  2.1%  0.0%  48  1  st
3 53  The  use  of  systemic  corticosteroids  for  short  periods  of  time  MAY
be associated  with  serious  adverse  events,  particularly  in  the
presence  of  comorbidities.
95.8%  4.2%  0.0%  48  1  st
3 54  Patients  on  continuous  use  of  systemic  corticosteroid  therapy
should  be  regularly  monitored  regarding  the  assessment  of  weight
gain, diabetes,  dyslipidemia,  hypertension,  glaucoma,
osteoporosis,  cataracts,  or  neuropsychiatric  disorders.
100.0%  0.0%  0.0%  48  1  st
3 58  Patients  treated  with  chronic  systemic  corticosteroids  should  be
screened  for  diabetes  every  3  to  6  months  in  the  first  year  and
thereafter  every  year.
93.8%  4.1%  2.1%  48  1  st
3 59  Patients  treated  with  chronic  systemic  corticosteroids  should  be
screened  for  hypertension  every  3-6  months.
93.8%  2.0%  4.2%  48  1  st
3 60  Patients  treated  with  chronic  systemic  corticosteroids  should
undergo  weight  control  assessment  every  3-6  months.
91.7%  6.2%  2.1%  48  1  st
3 61  Patients  treated  with  chronic  systemic  corticosteroids  maintain
indication  for  pneumococcal  and  flu  vaccines.
100.0%  0.0%  0.0%  48  1  st
3 62  Patients  who  begin  dose  reduction/progressive  dose  reduction
aiming  chronic  systemic  corticosteroids  discontinuation  should  do
so with  a  slow  and  progressive  decrease.
100.0%  0.0%  0.0%  48  1  st
3 65  In  the  presence  of  normal  morning  serum  cortisol  levels  and
symptoms  of  adrenal  suppression  (i.e.  fatigue,  nausea,  vomiting,
diarrhea,  arthralgia,  hypotension,  psychiatric  symptoms),
patients  should  be  referred  to  endocrinology  for  complementary
evaluation.



































































Table  2  Results  of  the  Delphi  exercise:  items  reaching  consensus  in  the  2nd  round.






N.  answers Round  of
consensus
1 6
So  far,  cumulative  risk  of  systemic
corticosteroids  use  in  acute  exacerbations
of asthma  has  not  been  properly  valued.
1  st 81.2%  6.2%  12.7%  48
2nd2nd 87.0%  4.3%  8.7%  46
1 10
Exposure to  systemic  corticosteroids,  even
in short-term  administration,  i.e.  without
considering  chronic  exposure,  is  associated
with  an  increased  risk  of  adverse  events,
such  as  infections,  cardiovascular,
metabolic,  psychiatric,  ocular,
gastrointestinal  and  bone  complications.
1  st 81.3%  10.4%  8.3%  48
2nd2nd 91.3%  6.5%  2.2%  46
1 13
A nitric  oxide  (FeNO)  above  20  ppb  or  a
peripheral  blood  eosinophil  count  above
150 cells  per  l  is  suggestive  of  type  2
inflammation.
1  st 87.5%  2.0%  10.6%  48
2nd2nd 91.3%  4.4%  4.3%  46
2 24
Corticosteroid-resistant  asthma  or
insensitivity  to  corticosteroids,  which  might
occur  in  severe  asthma,  is  related  to
several  factors.
1  st  87.5%  10.4%  2.1%  48
2nd2nd 91.3%  6.5%  2.2%  46
2 28
In case  of  significant  adverse  events  with
clinical  harm,  chronic  systemic
corticosteroids  dose  should  be  reduced,
being  acceptable  some  worsening  of  asthma
control,  as  long  as  it  does  not  IMPLY
FURTHER  EXACERBATIONS.
1  st  81.2%  10.4%  8.5%  48
2nd2nd 89.1%  6.6%  4.3%  46
2 34
In patients  with  the  ability  to  self-manage
asthma,  in  the  face  of  an  exacerbation,  the
timely  initiation  of  therapy  with  a  short
cycle  of  systemic  corticosteroids  is  usually
effective  in  preventing  the  progression  of
the exacerbation  and  reducing  symptoms.
1  st  77.1%  12.5%  10.4%  48
2nd2nd 93.5%  0.0%  6.5%  46
2 35
The dose  reduction  of  chronic  systemic
corticosteroids  should  be  carried  out  under
the  direct  supervision  of  a  respiratory
specialist.
1  st 89.5%  2.1%  8.4%  48






























































Table  2  (Continued)






N.  answers  Round  of
consensus
2 40
The  dose  of  slow-release  systemic
corticosteroids  is,  in  most  cases,  higher
than  the  one  needed  to  control  the
exacerbation.
1  st  81.2%  8.3%  10.4%  48
2nd2nd 89.1%  4.4%  6.5%  46
2 45
Chronic systemic  corticosteroids
administration  in  asthmatics  can  anticipate
in decades  the  appearance  of  comorbidities
such  as  diabetes  mellitus  and
cardiovascular  disease  in  patients  with
susceptible  genetic  background.
1  st  87.5%  6.5%  6.5%  48
2nd2nd 93.5%  4.3%  2.2%  46
3 48
There  are  no  differences  in  the  frequency
of  adverse  events  between  intramuscularly
or orally  administered  corticosteroids.
1  st  16.7%  8.3%  75.0%  48
2nd2nd 8.7%  4.3%  87.0%  46
3 49
Adverse events  related  to  the  use  of
chronic  systemic  corticosteroid  therapy  are
dose  dependent.
1  st  77.1%  14.6%  8.3%  48
2nd2nd 89.1%  6.6%  4.3%  46
3 51
Systemic corticotherapy  is  associated  with
an increase  in  health  expenditure,  partly
due  to  related  adverse  events  management.
1  st  87.5%  10.4%  2.1%  48
2nd2nd 95.7%  2.1%  2.2%  46
3 55
Patients under  chronic  systemic
corticosteroid  therapy  should  perform  bone
densitometry  every  2  years.
1  st  85.4%  10.4%  4.7%  48
2nd2nd 89.1%  10.9%  0.0%  46
3 56
Patients treated  with  chronic  systemic
corticosteroids  should  undergo  annual  eye
screening.
1  st  89.6%  8.3%  2.1%  48
2nd2nd 93.0%  7.0%  0.0%  46
3 57
Patients treated  with  chronic  systemic
corticosteroids  should  be  screened  for  lipid
disorders  after  the  first  month  and
thereafter  every  6  to  12  months.
1  st  87.6%  6.2%  6.2%  48



































































Table  3  Results  of  the  Delphi  exercise:  items  reaching  consensus  in  the  3rd  round.
Topic Item  Statements  Rounds Positive  agreement Neutral  opinion Negative  agreement N.  answers Round  of  consensus
1 8
Systemic  corticosteroids  are  one  of  the
adjuvant  therapies  for  severe  asthma.
1  st 66.7%  10.4%  22.9%  48
3rd2nd 80.4%  6.5%  13.1%  46
3rd 89.1%  0.0%  10.9%  46
1 14
Asthmatic patients  treated  with  systemic
corticosteroids  or  high  dose  inhaled
corticosteroids  may  have  a  deceivingly
reduction  on  type  2  inflammation  signals.
1  st 85.4%  10.4%  4.2%  48
3rd2nd 84.8%  10.8%  4.4%  46
3rd 95.7%  4.3%  0.0%  46
1 15
Even with  the  availability  of  biologic
agents,  a  proportion  of  patients  will  still
need  systemic  corticosteroids  to  control
their  severe  asthma.
1  st 75.0%  14.5%  10.5%  48
3rd2nd 84.8%  8.7%  6.5%  46
3rd 91.3%  4.3%  4.3%  46
1 18
In patients  with  uncontrolled  severe  asthma
which  are  not  eligible  for  biologics  (e.g.
non type  2  asthma),  systemic
corticosteroids  may  be  attempted  in  order
to achieve  control.
1  st 81.2%  12.5%  6.3%  48
3rd2nd 82.6%  10.9%  6.5%  46
3rd 89.1%  8.7%  2.2%  46
2 25
In corticosteroid-insensitive  asthma,
effective  treatment  with  oral  systemic
corticosteroids  might  only  be  achieved  with
higher  doses.
1  st 63.9%  19.1%  17.0%  47
3rd2nd 71.7%  15.2%  13.0%  46
3rd 87.0%  4.3%  8.7%  46
2 27
Titration of  systemic  corticosteroids  dose,
in order  to  control  severe  asthma,  should
not exceed  40  mg  prednisone  or  equivalent
daily,  since  it  is  unlikely  that  higher  doses
have further  benefits
1  st  72.9%  14.5%  12.7%  48
3rd2nd 80.4%  8.7%  10.9%  46
3rd 87.0%  6.5%  6.5%  46
2 29
In case  of  significant  adverse  events  with
clinical  harm,  chronic  systemic
corticosteroids  dose  should  be  reduced
being  acceptable  some  worsening  of  asthma
control,  as  long  as  it  does  not  IMPLY
WORSENING  OF  SYMPTOMS
1  st  68.7%  16.6%  14.8%  48
3rd2nd 84.8%  4.4%  10.8%  46
3rd 89.1%  0.0%  10.9%  46
2 30
In case  of  significant  adverse  events  with
clinical  harm,  chronic  systemic
corticosteroids  dose  should  be  reduced,
being  acceptable  some  worsening  of  asthma
control,  as  long  as  it  does  not  IMPLY  A
QUALITY  OF  LIFE  DETERIORATION.
1  st  68.7%  14.5%  16.7%  48
3rd2nd 82.6%  4.4%  13.0%  46
3rd 88.9%  0.0%  11.1%  45
2 32
In severe  asthma  there  is  no  need  to
escalate  the  chronic  systemic
corticosteroids  dose
1  st  8.3%  16.7%  75.0%  48
3rd2nd 4.4%  10.8%  84.7%  46
3rd 2.2%  10.8%  87.0%  46
2 37
Gradual dose  reduction  of  chronic  systemic
corticosteroids  avoids  exacerbations,  as  the
minimum  necessary  dose  can  be  titrated.
1  st  72.9%  16.7%  10.4%  48
3rd2nd 84.8%  13.0%  2.2%  46






























































Table  4  Results  of  the  Delphi  exercise:  items  without  consensus.






N.  answers  Round  of  consensus
1 5
So  far,  chronic  maintenance  therapeutic  with
systemic  corticosteroids  in  severe  asthma  has
been  avoided.
1  st  58.3%  9.8%  31.9%  48
Not
reached
2nd 63.0%  6.5%  30.5%  46
3rd 65.2%  2.2%  32.6%  46
1 17
In  patients  with  biologic  criteria,  systemic
corticosteroid  therapy  should  not  be  initiated
because  of  the  risk  of  incurring  complications
inherent  to  systemic  corticosteroid  therapy.
1  st  54.2%  8.3%  37.5%  48
Not
reached
2nd 76.1%  0.0%  23.9%  46
3rd 82.6%  0.0%  17.4%  46
2 22
Doses until  5  mg  prednisone  or  equivalent  a
day  are  considered  low  chronic  systemic
corticosteroid  doses
1  st  70.8%  16.5%  12.7%  48
Not
reached
2nd 78.3%  13.0%  8.7%  46
3rd 82.6%  10.9%  6.5%  46
2 23
Doses above  5  mg  of  prednisone  or  equivalent  a
day  are  considered  high  chronic  systemic
1  st  56.2%  20.8%  23.0%  48
Not
reached
2nd 60.8%  19.6%  19.6%  46
3rd 69.6%  17.4%  13.0%  46
2 31
Facing relevant  side  effects  with  serious
clinical  damages,  chronic  systemic
corticosteroids  dose  should  be  reduced
although  with  some  acceptable  worsening  of
asthma  control,  as  long  as  it  does  not  IMPLY
THE  DECLINE  OF  PULMONARY  FUNCTION.
1  st  52.0%  18.8%  29.2%  48
Not
reached
2nd 67.4%  8.7%  23.9%  46
3rd 76.1%  4.3%  19.6%  46
2 33
Monitoring inflammation  biomarkers  (e.g.,
exhaled  nitric  oxide,  peripheral  blood
eosinophil  count)  is  useful  for  titrating  the
chronic  systemic  corticosteroids  dose  in  the
long  term.
1  st  37.5%  33.3%  29.2%  48
Not
reached
2nd 36.9%  41.3%  21.7%  46



































































Table  4  (Continued)






N.  answers Round  of  consensus
2 39
Intramuscular  injections  of  depot
corticosteroids  are  as  effective  as  oral
corticosteroids  in  preventing  asthma
exacerbations.
1  st 22.9%  14.6%  62.5%  48
Not
reached
2nd 21.7%  10.9%  67.4%  46
3rd 21.7%  8.7%  69.6%  46
2 42
Titration of  chronic  systemic  corticosteroids
dose based  on  biomarkers  results  in  a  larger
reduction  of  exacerbations,  when  compared  to
the  dose  titration  solely  based  on  clinical
markers.
1  st 47.9%  37.5%  14.6%  48
Not
reached
2nd 52.2%  37.0%  10.8%  46
3rd 52.2%  41.3%  6.5%  46
3 46
A patient  treated  with  chronic  systemic
corticosteroids  is  at  risk  of  being  on  long-term
prednisone,  as  therapy  may  not  be  able  to  be
stopped  due  to  adrenal  suppression.
1  st 56.2%  18.8%  25.0%  48
Not
reached
2nd 65.2%  8.7%  26.1%  46
3rd 67.4%  8.7%  23.9%  46
3 52
The use  of  systemic  corticosteroids  for  short
periods  of  time  is  NOT  associated  with  serious
adverse  events.
1  st 22.9%  20.8%  56.3%  48
Not
reached
2nd 17.4%  17.4%  65.2%  46
3rd 8.7%  8.7%  82.6%  46
3 63
Whenever physiological  doses  are  reached,
plasmatic  levels  of  ACTH  and  plasmatic
cortisol  should  be  measured
1  st 64.6%  22.9%  12.5%  48
Not
reached
2nd 73.9%  21.7%  4.4%  46
3rd 82.6%  17.4%  0.0%  46
3 64
Morning serum  cortisol  levels  should  guide  the
reduction  of  chronic  systemic  corticosteroids
below  physiologic  dose
1  st 50.0%  29.2%  20.8%  48
Not
reached
2nd 60.8%  26.1%  13.1%  48
3rd 63.0%  34.8%  2.2%  46
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Figure  1  Flowchart  of  the  con
ounds  was  -3.7%  [IQR  -4.2,  0.1];  and  between  2nd  and  3rd
ounds  was  -2.2%  [IQR  -4.4,  -0.5]).  Statements  n.  17  (topic
)  and  34  (topic  2)  presented  the  highest  changes  in  agree-
ent  rates,  expressed  in  percentage  points  (pp):  21.9  pp  and
6.4  pp,  respectively,  between  1st  and  2nd  rounds.  Between
nd  and  3rd  rounds,  statements  14  (topic  1)  and  25  (topic
)  were  those  with  highest  variation  (10.9  pp  and  15.2  pp
espectively).  Statements  n.  17  (topic  1)  and  52  (topic  3)
howed  more  variation  in  the  disagreement  rates:  -13.6  pp
between  1st  and  2nd  rounds)  and  17.4  pp  (between  2nd  and
rd  rounds),  respectively  (see  supplemental  material  Table
2).
iscussion
e  were  able  to  perform  a  nationwide  and  multidisciplinary
elphi  consensus  with  the  participation  of  experts  from  the
ifferent  clinical  specialties  that  daily  treat  adult  patients
ith  severe  asthma  in  Portugal.  The  high  level  of  compli-
nce  among  panelists  with  this  exercise  (over  95%  in  all
ounds)  may  reveal  the  perception  of  relevance  of  the  topic
or  clinical  practice.
The  Delphi  technique  has  the  advantage  of  avoiding  the
ominant  personality  effect  by  using  anonymous  responses,
nd  allows  for  the  re-evaluation  of  panelists  opinions  in
he  light  of  group  answers,  without  losing  the  gains  from
ace-to-face  discussions.24--26 Studies  also  stress  the  added
alue  of  comments  along  with  personal  interaction  as  a
ay  of  supporting  the  change  on  the  level  of  agreement
etween  rounds  or  to  detail  the  reasons  behind  a  lack  of
onsensus.27,28
Almost  half  of  the  statements  enrolled  in  this  DelphiPlease  cite  this  article  in  press  as:  Chav
https://doi.org/10.1016/j.pulmoe.2020.10.002
uestionnaire  obtained  positive  consensus  by  the  end  of
ound  one;  ten  of  them  with  a  concordance  equal  100%.





us  obtained  in  the  Delphi  study.
The  lack  of  consensus  in  statement  5  ‘‘So  far,  chronic
aintenance  therapeutic  with  systemic  corticosteroids  in
evere  asthma  has  been  avoided’’  may  be  due  to  lack  of  clar-
ty  of  the  text,  leading  to  misinterpretation.  Nevertheless,
lmost  two-thirds  of  the  panelists  considered  that  there  is
o  overuse  of  OCS  in  the  maintenance  therapeutics  of  severe
sthma,  which  is  far  from  the  reality  in  our  country,29 and
herefore  should  be  addressed  in  future  educational  actions.
n  the  other  hand,  there  was  a  consensus  (87%  of  positive
greement)  that  further  actions  for  the  assessment  of  the
umulative  risk  of  OCS  use  in  acute  asthma  exacerbations
re  needed  (statement  6  ‘‘So  far,  cumulative  risk  of  sys-
emic  corticosteroids  use  in  acute  exacerbations  of  asthma
as  not  been  properly  valued’’).
For  some  statements,  such  as  item  9  (‘‘Chronic  exposure
o  systemic  corticosteroids  is  significantly  associated  with
n  increase  of  adverse  events,  such  as  infections,  cardio-
ascular,  metabolic,  psychiatric,  ocular,  gastrointestinal  and
one  complications’’)  the  full  agreement  in  the  1st  round
as  expected  given  the  generic  non-specific  text.  Neverthe-
ess,  statement  10  (‘‘Exposure  to  systemic  corticosteroids,
ven  in  short-term  administration,  i.e.  without  consid-
ring  chronic  exposure,  is  associated  with  an  increased
isk  of  adverse  events,  such  as  infections,  cardiovascular,
etabolic,  psychiatric,  ocular,  gastrointestinal  and  bone
omplications’’)  only  achieved  consensus  in  the  2nd  round.
e  might  speculate  that  awareness  of  short-term  OCS  side-
ffects  is  lower  but  also,  we  should  recognize  that  the
tatement  did  not  quantify  the  increase  in  the  number  of
dverse  events  nor  define  the  meaning  of  short-term  admin-
stration.
The  positive  consensus  (91.3%)  obtained  for  statement
5  in  the  last  round  (‘‘Even  with  the  availability  of  bio-es  Loureiro  C,  et  al.  Pulmonol.  2020.
ogic  agents,  a  proportion  of  patients  will  still  need  systemic
orticosteroids  to  control  their  severe  asthma’’)  demon-
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Reducing  oral  corticosteroids  in  severe  asthma  (ROSA  Projec
other  therapies.  During  the  face-to-face  meeting,  the  com-
mittee  highlighted  that  even  with  the  availability  of  new
biologic  agents,  physicians  may  still  consider  the  use  of
OCS  for  severe  asthma.  Indeed,  an  important  percentage
of  severe  asthma  patients  are  not  eligible  for  the  already
available  biological  agents  and  so,  probably  given  the  clin-
ical  experience  with  OCS  in  type  2  asthma,  these  therapies
might  still  have  a  role.20,30 However,  the  positive  consen-
sus  (91.7%)  achieved  for  the  statement  16  at  the  1st  round
(‘‘A  severe  asthma  patient  with  more  than  2  severe  asthma
exacerbations  treated  with  systemic  corticosteroids,  or  an
asthma  related  hospitalization  in  the  last/past  year,  when-
ever  eligible,  should  be  treated  with  a  biologic  agent’’)
demonstrated  a  favorable  perception  for  using  biologic
agents.  This  emphasizes  an  especially  important  message
for  all  physicians  who  face  severe  asthma  patients  (both  in
acute  and  chronic  settings)  that  must  increase  their  aware-
ness  for  the  availability  of  these  novel  therapies,  reinforcing
the  need  for  a  timely  referral.
Consensus  was  not  reached  for  statement  17:  ‘‘In
patients  with  biologic  criteria,  systemic  corticosteroid  ther-
apy  should  not  be  initiated  because  of  the  risk  of  incurring
complications  inherent  to  systemic  corticosteroid  therapy’’.
This  may  have  occurred  given  the  existing  delays  for  the
approval  of  use  of  biologic  agents  in  our  country,  which
contributes  to  increasing  the  number  of  untreated  patients
who  need  to  initiate  OCS.  The  discussion  with  the  experts
revealed  that  OCS  should  usually  be  avoided  before  biolog-
ics,  but  when  justified,  they  can  be  initiated  at  a  minimum
effective  dosage  for  a  short  period  of  time.  This  means,  bio-
logic  agents  are  now  viewed  as  the  first  line  of  treatment
for  severe  asthma,  and  OCS  should  be  withdrawn  as  soon  as
possible  once  a  biologic  is  initiated.
Patients  that  do  not  respond  to  treatment  with  biolog-
ics  may  also  be  unresponsive  to  OCS,31,32 especially  because
there  are  clear  unmet  needs  requiring  novel  therapeutic
approaches  for  non-type  2  asthma.19,20 This  was  highlighted
by  both  statements  18  (‘‘In  patients  with  uncontrolled
severe  asthma  which  are  not  eligible  for  biologics  (e.g.  non
type  2  asthma),  systemic  corticosteroids  may  be  attempted
in  order  to  achieve  control’’)  and  19  (‘‘Patients  with  uncon-
trolled  severe  asthma  which  are  not  eligible  for  biologics
and  treated  with  OCS,  should  have  its  effectiveness  evalu-
ated  in  3−6  months.  That  evaluation  should  be  based  in
the  change  of  the  outcomes  previously  defined  for  that
specific  patient’’).  In  this  context,  treatment  with  OCS
still  appears  to  be  an  important  alternative  for  asthmatic
patients,  but  periodic  re-evaluation  and  tailored  treatment
towards  patients’  needs  are  paramount  to  demonstrate
the  added  value  of  this  approach.  If  the  added  value  is
not  reached,  therapeutic  strategies  must  be  reconsidered.
Asthma  control  encompasses  objective  clinical  outcomes
(e.g.  pulmonary  function  and  exacerbations),  but  also
patient-reported  outcomes  (PROs),  such  as  asthma  symp-
toms,  activity  levels,  health-related  quality  of  life  (HRQoL)
and  patient  satisfaction.  PROs  are  important  complemen-
tary  measures  of  the  patient’s  health  care  experience  which
should  be  considered  when  selecting  treatment,  becausePlease  cite  this  article  in  press  as:  Chav
https://doi.org/10.1016/j.pulmoe.2020.10.002
they  supplement  physiologic  and  clinical  assessments  of
asthma  and  may  influence  compliance  with  therapy.33,34
The  high  positive  agreement  (95.8%)  for  statements  21







ontrol  should  be  pre-established  with  the  patient,  concern-
ng  various  parameters  to  be  considered,  as  exacerbations,
ymptoms,  quality  of  life,  respiratory  function  or  adverse
ffects  of  therapy’’),  together  with  the  lack  of  consensus
or  statement  31  (‘‘Facing  relevant  side  effects  with  seri-
us  clinical  damages,  chronic  systemic  corticosteroids  dose
hould  be  reduced  although  with  some  acceptable  worsening
f  asthma  control,  as  long  as  it  does  not  IMPLY  THE  DECLINE
F  PULMONARY  FUNCTION’’)  may  reveal  that  some  degree
f  lung  function  deterioration  may  be  more  acceptable  com-
ared  to  outcomes  such  as  worsening  of  symptoms  or  quality
f  life  (HRQoL).
The  lack  of  consensus  in  statements  22  and  23  (‘‘Doses
ntil  5  mg  prednisone  or  equivalent  a  day  are  considered  low
hronic  systemic  corticosteroid  doses’’  and  ‘‘Doses  above
 mg  of  prednisone  or  equivalent  a  day  are  considered  high
hronic  systemic’’,  respectively),  may  have  occurred  given
he  differences  in  the  definition  of  ‘low  dose’.  Although  a
aily  dose  of  5  mg  of  prednisone  or  equivalent  is  usually
ssumed  a  low  dose,4,5 further  evidence  on  these  thresholds
ay  be  necessary.
Statements  25  (‘‘In  corticosteroid-insensitive  asthma,
ffective  treatment  with  oral  systemic  corticosteroids  might
nly  be  achieved  with  higher  doses’’)  and  27  (‘‘Titration
f  systemic  corticosteroids  dose,  in  order  to  control  severe
sthma,  should  not  exceed  40  mg  prednisone  or  equivalent
aily,  since  it  is  unlikely  to  have  further  benefits  with  higher
ose’’),  both  of  them  with  positive  consensus  in  the  3rd
ound  (87.0%),  conceptualize  the  OCS  plateau  effect  for
nti-asthmatic  efficacy.  However,  higher  doses  than  40  mg
rednisone  daily,  or  equivalent,  should  be  avoided  because
here  is  an  increased  risk  of  adverse  events  without  any
vidence  of  added  benefits.4,5,35
The  lack  of  consensus  in  statement  39  ‘‘Intramuscular
njections  of  depot  corticosteroids  are  as  effective  as
ral  corticosteroids  in  preventing  asthma  exacerbations.’’
hould  be  interpreted  alongside  statements  40  (‘‘The  dose
f  slow-release  systemic  corticosteroids  is,  in  most  cases,
igher  than  the  one  needed  to  control  the  exacerbation’’)
nd  41  (‘‘The  use  of  slow-release  injectable  corticosteroids
hould  be  avoided’’)  which  obtained  positive  agreement  in
he  2nd  and  1st  rounds,  respectively.  These  results  indicate,
s  perceived  in  the  face-to-face  panel  meeting,  that  item
9  should  clearly  state  ‘in  the  treatment’  instead  of  ‘in  pre-
ention’.  Additionally,  long  acting  OCS  should  be  avoided  as
tated  in  the  rule:  lowest  dose,  shortest  treatment  duration.
tudies  highlight  the  relevance  of  the  cumulative  steroid
ose.36
The  discussion  of  inflammation  monitoring  in  asthma
statement  33  -  ‘‘Monitoring  inflammation  biomarkers  (e.g.,
xhaled  nitric  oxide,  peripheral  blood  eosinophil  count)
s  useful  for  titrating  the  chronic  systemic  corticosteroids
ose  in  the  long  term’’)  further  demonstrates  a  lack  of
onsensus,  probably  due  to  access  constraints  to  these
valuation  methods  rather  than  the  lack  of  perception
f  relevance  of  the  topic  by  the  experts.  Still,  as  shown
y  the  debate  from  statement  42  (‘‘Titration  of  chronic
ystemic  corticosteroids  dose  based  on  biomarkers  resultses  Loureiro  C,  et  al.  Pulmonol.  2020.
n  a larger  reduction  of  exacerbations,  when  compared
o  the  dose  titration  solely  based  on  clinical  markers’’)
he  literature  is  ambiguous  on  the  role  of  inflammation








































































ARTICLEULMOE-1547; No. of Pages 15
4  
omorbidities  secondary  to  OCS  side  effects  was  rated  as
mperative  by  the  experts  with  100%  positive  consensus
n  the  1st  round  (statement  54  ‘‘Patients  on  continuous
se  of  systemic  corticosteroid  therapy  should  be  regularly
onitored  regarding  the  assessment  of  weight  gain,  dia-
etes,  dyslipidemia,  hypertension,  glaucoma,  osteoporosis,
ataracts  or  neuropsychiatric  disorders’’),  revealing  the
eed  for  standardized  clinical  protocols  of  data  collection
nd  evaluation.
The  absence  of  consensus  in  statement  46  (‘‘A  patient
reated  with  chronic  systemic  corticosteroids  is  at  risk  of
eing  on  long-term  prednisone,  as  therapy  may  not  be  able
o  be  stopped  due  to  adrenal  suppression’’)  may  be  due  to
ifferent  reasons.  OCS  withdrawal  is  sometimes  associated
ith  adrenal  suppression  and  some  studies  find  that  roughly
0%  of  patients  develop  adrenal  suppression.15,30,38 Never-
heless,  as  no  protocols  to  routinely  evaluate  these  cases
xist,  this  might  correspond  to  an  underestimate  percent-
ge.  Keeping  in  mind  the  lack  of  guidance  not  only  on  OCS
se  in  asthma  context  but  also  on  how  to  monitor  thera-
ies  side  effects  and  withdrawals,  it  is  important  to  develop
rotocols  for  daily  practice.
The  different  interpretations  of  the  concept  of  ‘physio-
ogical  dose’  as  well  as  the  evaluation  methods  may  justify
he  lack  of  consensus  for  both  statement  63  (‘‘Whenever
hysiological  doses  are  reached,  plasmatic  levels  of  ACTH
nd  plasmatic  cortisol  should  be  measured’’)  and  state-
ent  64  (‘‘Morning  serum  cortisol  levels  should  guide  the
eduction  of  chronic  systemic  corticosteroids  bellow  phys-
ologic  dose’’).  Based  on  the  discussion  with  the  experts,
he  steering  committee  stated  that  morning  serum  cortisol
est  should  be  carried  out  whenever  possible  because  it  is
n  easy,  low-cost  and  accessible  test  which  assists,  among
ther  things,  the  evaluation  of  adrenal  insufficiency.
Despite  evident  strengths  our  study  has  some  limita-
ions.  Our  discussion  is  based  on  expert  opinion  rather  than
atient  data;  however,  the  Delphi  technique  is  a  widely
sed  and  accepted  method  for  achieving  convergence  and
s  well  recognized  as  a  qualitative  technique  for  data  elici-
ation.  The  Delphi  panel  included  only  clinical  specialists  in
sthma,  selected  as  key  opinion  leaders,  with  the  ability  to
escribe  clinical  practice  in  Portugal,  in  secondary  special-
zed  care  level.  However,  other  healthcare  professionals,  in
ther  healthcare  settings,  may  have  different  opinions.
onclusions
he  results  of  this  study  could  be  considered  as  a  first  step
owards  providing  updated  consensus  of  OCS  use  for  asthma
anagement  in  Portugal,  and  should  be  supplemented  by
dditional  studies,  exploring  treatment  algorithms,  therapy
ccess,  patient’s  adherence,  and  costs.
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